The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines

Blood

Volumn 98, Issue 8, 2001, Pages 2293-2300

  Hamaia, Samir ^a,b   Li, Chengyao ^a,b   Allain, Jean Pierre ^a,b,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c East Anglia Blood Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; CELL SURFACE RECEPTOR; IMMUNOGLOBULIN G; RECOMBINANT PROTEIN; VIRUS GLYCOPROTEIN;

ARTICLE; CELL ADHESION; CELL STRAIN U937; CONTROLLED STUDY; DOSE RESPONSE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; RNA VIRUS INFECTION; TARGET CELL; THROMBOCYTE; VIRUS CELL INTERACTION;

EID: 0035889127     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.8.2293     Document Type: Article

References (69)

1. Bik T, Sarov I, Livne A. Interaction between vaccinia virus and human blood platelets. Blood. 1982;59:482-487.
2. Lee TH, Stromberg RR, Henrard D, Busch MP. Effect of platelet-associated virus on assays of HIV-1 in plasma [letter; comment]. Science. 1993;262:1585-1586.
3. Bruisten S, van Gemen B, Koppelman M, et al. Detection of HIV-1 distribution in different blood fractions by two nucleic acid amplification assays. AIDS Res Hum Retroviruses. 1993;9:259-265.
4. Borgia G, Reynaud L, Cicciarello S, et al. Thrombocytopenia and AIDS: possible direct role of HIV [letter]. AIDS 1996;10:1606-1608.
5. Ho DD, Moudgil T, Alam M. Quantitafion of human immunodeficiency virus type 1 in the blood of infected persons [see comments]. N Engl J Med. 1989;321:1621-1625.
6. Zhu YS, Gong Y, Cimino GD. Quantitative analysis of HIV-1 RNA in plasma preparations. J Virol Methods. 1995;52:287-299.
7. Holodniy M, Margolis D, Carroll R, Todd J, Mole L. Quantitative relationship between platelet count and plasma virion HIV RNA[letter]. AIDS 1996;10:232-233.
8. Terada H, Baldini M, Ebbe S, Madoff MA. Interaction of influenza virus with blood platelets. Blood. 1996;28:213-228.
9. Forghani B, Schmidt NJ. Association of herpes simplex virus with platelets of experimentally infected mice. Arch Virol. 1983;76:269-274.
10. Gavrilovskaya IN, Shepley M, Shaw R, Ginsberg MH, Mackow ER. beta3- Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc Natl Acad Sci U S A. 1998;95:7074-7079.
11. Gavrilovskaya IN, Brown EJ, Ginsberg MH, Mackow ER. Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins. J Virol. 1999;73:3951-3959.
12. Wang S, He R, Patarapotikul J, Innis BL, Anderson R. Antibody-enhanced binding of dengue-2 virus to human platelets. Virology. 1995;213:254-257.
13. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359-362.
14. Kuo G, Choo QL, Alter HJ, at al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989;244:362-364.
15. Rice CM. Flaviviridiae: the viruses and their replication. In: Fields BN, Knipe DM, Howley M, eds. Fields Virology. 3d ed. Philadelphia, PA: Lippincott-Raven; 1996:931-959.
16. Clarke B. Molecular virology of hepatitis C virus. J Gen Virol. 1997;78:2397-2410.
17. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science. 1992;258:135-140.
18. Nelson DR, Marousis CG, Davis GL, et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol. 1997;158:1473-1481.
19. Weiner A, Erickson AL, Kansopon J, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A. 1995;92:2755-2759.
20. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol. 1993;67:1385-1395.
21. Hijikata M, Kato N, Ootsuyama Y, Nakagawa M, Shimotohno K. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci U S A. 1991;88:5547-5551.
22. Santolini E, Migliaccio G, La Monica N. Biosynthesis and biochemical properties of the hepatitis C virus core protein. J Virol. 1994;68:3631-3641.
23. Deleersnyder V, Pillez A, Wychowski C, et al. Formation of native hepatitis C virus glycoprotein complexes. J Virol. 1997;71:697-704.
24. Dubuisson J, Hsu HH, Cheung RC, Greenberg HB, Russell DG, Rice CM. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol. 1994;68:6147-6160.
25. Rosa D, Campagnoli S, Moretto C, et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A. 1996;93:1759-1763.
26. Jackson P, Petrik J, Alexander GJ, Pearson G, Allain JP. Reactivity of synthetic peptides representing selected sections of hepatitis C virus core and envelope proteins with a panel of hepatitis C virus-seropositive human plasma. J Med Virol. 1997;51:67-79.
27. van Doorn LJ, Capriles I, Maertens G, et al. Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J Virol. 1995;69:773-778.
28. Farci P, Shimoda A, Wong D, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A. 1996;93:15394-15399.
29. Shang D, Zhai W, Allain JP. Broadly cross-reactive, high-affinity antibody to hypervariable region 1 of the hepatitis C virus in rabbits. Virology. 1999;258:396-405.
30. Shimizu YK, Igarashi H, Kiyohara T, et al. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology. 1996;223:409-412.
31. Zhou YH, Moriyama M, Esumi M. Multiple sequence-reactive antibodies induced by a single peptide immunization with hypervariable region 1 of hepatitis C virus. Virology. 1999;256:360-370.
32. Zhou YH, Shimizu YK, Esumi M. Monoclonal antibodies to the hypervariable region 1 of hepatitis C virus capture virus and inhibit virus adsorption to susceptible cells in vitro. Virology. 2000;269:276-283.
33. Zibert A, Meisel H, Kraas W, Schulz A, Jung G, Roggendorf M. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology. 1997;25:1245-1249.
34. Zibert A, Dudziak P, Schreier E, Roggendorf M. Characterization of antibody response to hepatitis C virus protein E2 and significance of hypervariable region 1 -specific antibodies in viral neutralization. Arch Virol. 1997;142:523-534.
35. Zibert A, Schreier E, Roggendorf M. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology. 1995;208:653-661.
36. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science. 1998;282:938-941.
37. Levy S, Todd SC, Maecker HT. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol. 1998;16:89-109.
38. Maecker HT, Todd SC, Levy S. The tetraspanin superfamily: molecular facilitators. FASEB J. 1997;11:428-442.
39. Flint M, Maidens C, Loomis-Price LD, et al. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol. 1999;73:6235-6244.
40. Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A. 1994;91:1294-1298.
41. Allander T, Forns X, Emerson SU, Purcell RH, Bukh J. Hepatitis C virus envelope protein E2 binds to CD81 of tamarins. Virology. 2000;277:358-367.
42. Meola A, Sbardellati A, Bruni Ercole B, et al. Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J Virol. 2000;74:5933-5938.
43. Monazahian M, Bohme I, Bonk S, et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Mad Virol. 1999;57:223-229.
44. Monazahian M, Kippenberger S, Muller A, et al. Binding of human lipoproteins (low, very low, high density lipoproteins) to recombinant envelope proteins of hepatitis C virus. Med Microbiol Immunol (Berl). 2000; 189:177-184.
45. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A. 1999;96:12766- 12771.
46. Bradley D, McCaustland K, Krawczynski K, Spelbring J, Humphrey C, Cook EH. Hepatitis C virus: buoyant density of the factor VIII-derived isolate in sucrose. J Med Virol. 1991;34:206-208.
47. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A. Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol. 1992;181:293-300.
48. Thomssen R, Bonk S, Thiele A. Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med Microbiol Immunol (Berl). 1993;182:329-334.
49. Hijikata M, Shimizu YK, Kato H, et al. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol. 1993;67:1953-1958.
50. Kanto T, Hayashi N, Takehara T, et al. Density analysis of hepatitis C virus particle population in the circulation of infected hosts: implications for virus neutralization or persistence. J Hepatol. 1995;22:440-448.
51. Tsai JF, Jeng JE, Chang WY, Ho MS, Lin ZY, Tsai JH. Circulating immune complexes in chronic hepatitis C. J Med Virol. 1995;46:12-17.
52. Tsai JF, Jeng JE, Chang WY, Ho MS, Lin ZY, Tsai JH. Increased IgM-containing circulating immune complexes in patients co-infected with hepatitis C and hepatitis B. Medicine (Baltimore). 1995;74:136-143.
53. Korenaga M, Hino K, Okazaki M, Okuda M, Okita K. Differences in hypervariable region 1 quasispecies between immune complexed and nonimmune complexed hepatitis C virus particles. Biochem Biophys Res Commun. 1997;240:677-682.
54. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol. 1994;68:1494-1500.
55. Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody- mediated in vitro neutralization. Proc Natl Acad Sci U S A. 1994;91:7792-7796.
56. Oren R, Takahashi S, Doss C, Levy R, Levy S. TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol. 1990;10:4007-4015.
57. Weiner AJ, Brauer MJ, Rosenblalt J, et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology. 1991;180:842-848.
58. Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci U S A. 1991;88:3392-3396.
59. Weiner AJ, Geysen HM, Christopherson C, et al. Evidence for immune selection ol hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci U S A. 1992;89:3468-3472.
60. Taniguchi S, Okamoto H, Sakamoto M, et al. A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/NS1 protein: implication for an escape from antibody. Virology. 1993;195:297-301.
61. Kato N, Sekiya H, Ootsuyama Y, et al. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol. 1993;67:3923-3930.
62. Kato N, Ootsuyama Y, Sekiya H, et al. Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. J Virol. 1994;68:4776-4784.
63. Sekiya H, Kato N, Ootsuyama Y, Nakazawa T, Yamauchi K, Shimotohno K. Genetic alterations of the putative envelope proteins encoding region of the hepatitis C virus in the progression to relapsed phase from acute hepatitis: humoral immune response to hypervariable region 1. Int J Cancer. 1994;57:664-670.
64. Lesniewski RR, Boardway KM, Casey JM, et al. Hypervariable 5′-terminus of hepatitis C virus E2/NS1 encodes antigenically distinct variants. J Med Virol. 1993;40:150-156.
65. Scarselli E, Cerino A, Esposito G, Silini E, Mondelli MU, Traboni C. Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (gp70) hypervariable region 1 in viremic hepatitis C virus-infected patients. J Virol. 1995; 69:4407-4412.
66. Flint M, Dubuisson J, Maidens C, et al. Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein. J Virol. 2000;74:702-709.
67. Higginbottom A, Quinn ER, Kuo CC, et al. Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J Virol. 2000;74:3642-3649.
68. Takikawa S, Ishii K, Aizaki H, et al. Cell fusion activity of hepatitis C virus envelope proteins. J Virol. 2000;74:5066-5074.
69. Dubuisson J, Rice CM. Hepatitis C virus glycoprotein folding: disulfide bond formation and association with calnexin. J Virol. 1996;70:778-786.